MedPath

Efficacy of Physiotherapy for Urinary Incontinence in Women With a Puborectalis Avulsion

Not Applicable
Completed
Conditions
Postpartum
Physiotherapy
Urinary Incontinence
Pelvic Floor; Perineal Rupture, Obstetric
Interventions
Procedure: Multimodal physiotherapy
Registration Number
NCT03254355
Lead Sponsor
Université de Sherbrooke
Brief Summary

Childbirth is a major risk factor for pelvic floor muscle (PFM) trauma. In one third of women, stretching of the PFM will result in an avulsion injury (i.e. disconnection of the muscle from its insertion points on the pubic symphysis). Recent advances in imaging have led to the discovery of this previously unknown major injury and further research now enables its diagnosis with readily available techniques. Avulsion injury has alarming consequences because it has been associated with a higher rate of urinary incontinence in the postpartum period as well as the long-term development of other major urogynecological conditions such as pelvic organ prolapse and anal incontinence. Women with avulsion not only suffer from severe symptoms with significant related impacts on physical activities, overall well-being and quality of life, but they also present a higher rate of surgical failures. Moreover, it is still unknown whether the most recommended first-line treatment for urinary incontinence -PFM physiotherapy- is effective in women with this major trauma. Until now, only a pilot study conducted by our team supports the rationale and the efficacy of physiotherapy for improving PFM function in women with avulsion, despite their major muscle injury.

Primary objective: To evaluate the efficacy of physiotherapy for urinary incontinence in women with avulsion at 9-months after randomization compared to a waiting-list control group.

Secondary objectives:

1. To compare physiotherapy to the control group after treatment and at 9-months after randomization in terms of: a) incontinence and prolapse (objective quantification, symptoms and related impact); b) PFM morphology and function; c) sexual function; d) self-efficacy; e) cost analysis; f) treatment satisfaction and impression of change.

2. To investigate the impact of the severity of the avulsion (i.e. unilateral or bilateral) on the response to physiotherapy treatment on the aforementioned outcomes.

Detailed Description

This is a multicenter randomized controlled trial using a parallel group design that involves women with a confirmed diagnosis of avulsion and suffering from urinary incontinence. Participants will be randomized into either physiotherapy or a waiting-list control group. Both groups will be evaluated at baseline, post-treatment (3 months post-randomization) and 9 months after randomization. Women in the control group will receive full-body relaxation massage which has shown no effect on continence but was selected to control for effects of attention received by the therapist. After the 9-month assessment, women assigned to the control group will receive the same physiotherapy treatment and undergo a last assessment.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
126
Inclusion Criteria
  • 18-45 years old
  • Postpartum women (≥ 1 vaginal delivery at term (≥ 37 weeks) and ≥ 3 months postpartum
  • ≥ 3 urinary incontinence episodes per week over the last 3 months (Symptoms of incontinence must be associated predominantly or solely with stress urinary incontinence (as opposed to urge incontinence) which will be determined with a recommended and validated diagnosis questionnaire (Questionnaire for Urinary Incontinence Diagnosis))
  • Women with diagnosis avulsion injury
Exclusion Criteria
  • Pregnancy or postmenopausal
  • Previous pelvic irradiation, urogynecological surgery, or PFM physiotherapy after the avulsion occurred
  • Significant prolapse (≥3 degree)
  • Incontinence due to other causes such as infection, neurological diseases, voiding difficulties
  • Any other acute or chronic medical problems likely to interfere with treatment or evaluation such as cancer, chronic constipation (Rome III criteria), obesity (body mass index >35), pacemaker, bladder stimulator
  • Medication or ongoing treatment likely to interfere with incontinence

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Multimodal physiotherapyMultimodal physiotherapy12 weeks of weekly multimodal physiotherapy treatments
Primary Outcome Measures
NameTimeMethod
Percent reduction in the number of urinary incontinence episodesbaseline, post-treatment (3 months post-randomization) and 9 months after randomization

The 7-day bladder diary was selected as the primary outcome to measure urinary leakage reduction

Secondary Outcome Measures
NameTimeMethod
Change in symptoms and impact of incontinence and other urogynecological conditionsbaseline, post-treatment (3 months post-randomization) and 9 months after randomization

Evaluated with ICI Modular Questionnaires (ICIQ), Pelvic Floor Distress Inventory (PFDI), Pelvic Floor Impact Questionnaire (PFIQ-SF) and Pelvic Organ Prolapse Symptom score (POP-SS)

Change in sexual functionbaseline, post-treatment (3 months post-randomization) and 9 months after randomization

Evaluated with Female Sexual Function Index (FSFI) and Pelvic Organ Prolapse/Incontinence Sexual Questionnaire (PISQ-SF)

Change in pelvic floor muscle morphometry and functionbaseline, post-treatment (3 months post-randomization) and 9 months after randomization

Evaluated with transperineal ultrasound and dynamometry

Change in severity of prolapsebaseline, post-treatment (3 months post-randomization) and 9 months after randomization

Evaluated with POP-Q assessment

Change in self-efficacybaseline, post-treatment (3 months post-randomization) and 9 months after randomization

Evaluated with Broom Pelvic Muscle Self-Efficacy Scale

Cost analysisbaseline and 9 months after randomization

Evaluated with Dowell-Bryant Incontinence Cost Index (DBICI)

Treatment satisfaction and impression of changebaseline, post-treatment (3 months post-randomization) and 9 months after randomization

Evaluated with Patient Satisfaction Questionnaire (PSQ) and Patient's Global Impression of Change (PGIC)

Trial Locations

Locations (1)

Centre Hospitalier Universitaire de Sherbrooke

🇨🇦

Sherbrooke, Quebec, Canada

© Copyright 2025. All Rights Reserved by MedPath